NeuroAiD(TM), a Stroke Treatment Based on Traditional Chinese Medicine, More than Doubles the Chances of Achieving Independence after Stroke - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
NeuroAiD(TM), a Stroke Treatment Based on Traditional Chinese Medicine, More than Doubles the Chances of Achieving Independence after Stroke


NeuroAiD(TM), a Stroke Treatment Based on Traditional Chinese Medicine, More than Doubles the Chances of Achieving Independence after Stroke

PR Newswire

SINGAPORE, March 19, 2013 /PRNewswire/ -- Authors of a medical paper published in this month's Cerebrovascular Diseases journal found that NeuroAiD™, developed by Moleac, significantly improves patients' independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely.  The study also showed that NeuroAiD™ improved patients' chances of performing daily activities after stroke.

Stroke is one of the leading causes of death worldwide and occurs every 2 seconds. Each year, 20 million people suffer from the devastating disease. There are only few effective, generally accepted and specific treatments for stroke, like thrombolytic treatment for highly selected patients. Therefore, there is an increasing need for multi-model therapies to help more patients recover quickly and effectively from stroke.

Herbal supplements have been demonstrated to have antioxidant, anti-inflammatory, and anti-glutamate effects, making them an attractive option to be investigated for stroke recovery. Thus, as Dr. Christopher Chen, one of the authors of the paper, says, "confirmation of the effectiveness of herbal supplements could have a great impact on stroke management". The paper updates the meta-analysis, published in Stroke journal in 2009 to include all clinical data available since 2009 on NeuroAiD™ and provides an overall assessment of the beneficial effects of NeuroAiD™ in improving functional and motor outcomes in the recovery after a stroke.

About Moleac

To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Traditional Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers' unaddressed needs. Moleac's neurorestorative drug NeuroAiD™ reaches patients in more than 30 countries.

Contact

To learn more about the medical paper and for interview requests, please contact:

Ms Fahima Khail
Global Marketing and Product  Manager
Email: Fahima.Khail@moleac.com
Tel. No.: +65 6478 9430 Ext.: 124
Mobile No.: +65 8427 6702
Moleac Pte Ltd Helios #09-08, 11 Biopolis Way Singapore 138667
www.moleac.com

SOURCE Moleac

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document

Click here